1. Home
  2. Medicines
  3. Primary & Specialty Care
  4. Cardiovascular

Cardiovascular

At Dompé, we combine scientific expertise and innovative therapies to support heart health, prevent arrhythmias, and improve quality of life for patients at every stage.

Growing Incidence of Cardiovascular Pathologies

Bisoprolol and flecainide are positioned as first‑line therapies for their respective indications, namely heart failure and atrial fibrillation. Heart failure has an age‑related prevalence of 1–2% in the adult population, rising to over 10% in individuals above 70 years of age. Its incidence is increasing, reaching 3–5 cases per 1,000 person‑years (2021 ESC Guidelines on Heart Failure).

The benefits of beta-blockers, such as bisoprolol, are supported by clinical guidelines and robust scientific evidence, including the most recent findings (2023 ESC Guidelines on Heart Failure).

Heart and Blood Health with a Cutting‑Edge Approach

Atrial fibrillation—the most common arrhythmia—has a prevalence of 2–4% in the adult population, with projections indicating a 2‑ to 3‑fold increase due to population aging (ESC 2020 Guidelines – Atrial Fibrillation). Flecainide belongs to a therapeutic class whose value is supported by emerging evidence and international guidelines. Once‑daily flecainide is recommended by the 2024 ESC Guidelines for the diagnosis and management of atrial fibrillation.

Completing the area is Ferrofast, a liposomal iron‑based food supplement distinguished by its high bioavailability and excellent tolerability.

Frequil

Sequacor

Ferrofast Forte

These images refer to products that are registered and marketed in Italy.